YM BioSciences Reports CYT387 Phase I/II Results Selected by ASH Program Committee
News Oct 12, 2012
YM BioSciences Inc. has announced that the results of its Phase I/II Study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis, have been selected by the ASH Program Committee for presentation in an Oral Session at the 2012 Annual Meeting of the American Society of Hematology to be held in Atlanta, Georgia on December 9, 2012.
"CYT387 could prove to be an important and differentiated therapeutic for patients with myelofibrosis; the interim data we have reported to date have been highly encouraging," said Dr. Nick Glover, President and CEO of YM BioSciences.
Dr. Glover continued, "We look forward to the release of final nine-month data from the Phase I/II CYT387 study at ASH, as well as further ongoing data from the many patients who continue to benefit from the drug in its Extension trial."
Title: Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
Session Name: 634. Myeloproliferative Syndromes - Clinical: Myeloproliferative Neoplasms - Novel Therapies I
Session Date: Sunday, December 9, 2012; 4:30 PM - 6:00 PM (Presentation Time: 5:15 PM)
Location: Georgia World Congress Center, Room B213-B214
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE